The completion of patient treatment in this pivotal Phase 3 trial is a major derisking milestone, but the binary outcome (top-line data) is not due until mid-CY2027. Traders should monitor for any interim data or regulatory updates. The RMAT designation and large addressable market support a bullish view, but the long timeline to data readout introduces uncertainty.
Price Chart
Executive Summary
Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, randomizing and treating 350 patients. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, enabling priority review upon BLA filing.
Key Facts
- Completed patient treatment in pivotal Phase 3 trial MSB-DR004 for rexlemestrocel-L in chronic low back pain (CLBP) associated with degenerative disc disease.
- 350 patients randomized and treated with either rexlemestrocel-L or sham injection.
- Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
- Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, allowing priority review upon BLA filing.
- Top-line results expected in mid-CY2027 after last patient completes 12-month follow-up.
- CLBP due to degenerative disc disease has a U.S. prevalence of over 7 million people.
- Company claims potential peak year revenue of >US$10 billion with single-digit market penetration.
Financial Impact
Potential peak year revenue >US$10 billion claimed by company for single-digit market penetration in CLBP/DDD indication.
Risk Factors
- Top-line results may fail to meet primary endpoint, leading to significant downside.
- Long timeline to data (mid-CY2027) means no near-term catalyst from this trial.
- Company's peak revenue estimates are forward-looking and unvalidated.
- Manufacturing or regulatory hurdles could delay BLA submission or approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access